carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - myeloma multiplex - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
thiotepa fresenius kabi 100 mg por oldatos infúzióhoz való koncentrátumhoz
fresenius kabi hungary kft. - thiotepa -
thiotepa fresenius kabi 15 mg por oldatos infúzióhoz való koncentrátumhoz
fresenius kabi hungary kft. - thiotepa -
thiotepa medac 15 mg por oldatos infúzióhoz való koncentrátumhoz
medac gmbh - thiotepa -
thiotepa medac 100 mg por oldatos infúzióhoz való koncentrátumhoz
medac gmbh - thiotepa -